CytomX Therapeutics Yönetim
Yönetim kriter kontrolleri 3/4
CytomX Therapeutics CEO'su Sean McCarthy, Aug2011 tarihinde atandı, in görev süresi 13.25 yıldır. in toplam yıllık tazminatı $ 2.61M olup, şirket hissesi ve opsiyonları dahil olmak üzere 25% maaş ve 75% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.71% ine doğrudan sahiptir ve bu hisseler $ 581.19K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.6 yıl ve 4.8 yıldır.
Anahtar bilgiler
Sean McCarthy
İcra Kurulu Başkanı
US$2.6m
Toplam tazminat
| CEO maaş yüzdesi | 25.0% |
| CEO görev süresi | 13.3yrs |
| CEO sahipliği | 0.7% |
| Yönetim ortalama görev süresi | 3.6yrs |
| Yönetim Kurulu ortalama görev süresi | 4.8yrs |
Son yönetim güncellemeleri
Recent updates
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues
Oct 26
CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments
Jul 15The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
Jun 15We Think Shareholders Are Less Likely To Approve A Pay Rise For CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO For Now
May 09CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling
May 02CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%
Apr 27CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town
Apr 25CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%
Mar 05CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Jan 19There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise
Nov 26We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely
Nov 17Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 29Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?
Feb 13Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%
Nov 10CytomX Therapeutics to cut workforce by about 40%
Jul 13CytomX says phase 2 study of breast cancer antibody treatment met main goal
Jul 06Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Jun 08Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?
Feb 10CytomX: Pullbacks Are Opportunities
Dec 14CytomX: Solving A Critical Problem In The High-Value ADC Space
Sep 15We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate
Aug 11CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$11m |
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$3m | US$652k | -US$569k |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$42m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$3m | US$623k | -US$99m |
| Sep 30 2022 | n/a | n/a | -US$149m |
| Jun 30 2022 | n/a | n/a | -US$143m |
| Mar 31 2022 | n/a | n/a | -US$132m |
| Dec 31 2021 | US$4m | US$616k | -US$116m |
| Sep 30 2021 | n/a | n/a | -US$72m |
| Jun 30 2021 | n/a | n/a | -US$64m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$3m | US$595k | -US$65m |
| Sep 30 2020 | n/a | n/a | -US$54m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$76m |
| Dec 31 2019 | US$4m | US$575k | -US$133m |
| Sep 30 2019 | n/a | n/a | -US$99m |
| Jun 30 2019 | n/a | n/a | -US$99m |
| Mar 31 2019 | n/a | n/a | -US$83m |
| Dec 31 2018 | US$5m | US$550k | -US$85m |
| Sep 30 2018 | n/a | n/a | -US$52m |
| Jun 30 2018 | n/a | n/a | -US$39m |
| Mar 31 2018 | n/a | n/a | -US$50m |
| Dec 31 2017 | US$3m | US$500k | -US$43m |
Tazminat ve Piyasa: Sean 'nin toplam tazminatı ($USD 2.61M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 655.02K ).
Tazminat ve Kazançlar: Sean 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Sean McCarthy (57 yo)
13.3yrs
Görev süresi
US$2,611,138
Tazminat
Dr. Sean A. McCarthy, D.Phil., serves as Independent Director at OncoResponse, Inc. since August 2021. He has been the Chief Executive Officer of CytomX Therapeutics, Inc. since August 2011 and has been it...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman & CEO | 13.3yrs | US$2.61m | 0.71% $ 581.2k | |
| Senior VP & Chief Scientific Officer | 1.8yrs | US$1.21m | 0.085% $ 69.8k | |
| Senior VP | 3.6yrs | US$1.05m | 0.079% $ 65.0k | |
| Chief Financial Officer | 2.2yrs | Veri yok | 0.039% $ 31.8k | |
| Senior VP | 6.5yrs | US$1.21m | 0.10% $ 81.8k | |
| Senior VP & Chief Human Resources Officer | no data | Veri yok | Veri yok | |
| Senior Vice President of Intellectual Property | 5.8yrs | Veri yok | Veri yok | |
| Chief Medical Officer | 1.3yrs | Veri yok | Veri yok | |
| Senior Vice President of Quality & Product Manufacturing | 1.8yrs | Veri yok | Veri yok | |
| Special Advisor to Chief Executive Officer | no data | US$273.54k | Veri yok |
3.6yrs
Ortalama Görev Süresi
55.5yo
Ortalama Yaş
Deneyimli Yönetim: CTMX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.6 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Chairman & CEO | 13.3yrs | US$2.61m | 0.71% $ 581.2k | |
| Independent Director | 5.5yrs | US$75.12k | 0.0066% $ 5.4k | |
| Member of Scientific Advisory Board | 4.8yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | no data | Veri yok | Veri yok | |
| Independent Director | 3.9yrs | US$78.62k | 0% $ 0 | |
| Independent Director | 5.9yrs | US$77.12k | 0% $ 0 | |
| Lead Independent Director | 9.2yrs | US$105.12k | 0% $ 0 | |
| Independent Director | 4.6yrs | US$80.62k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.9yrs | US$8.03m | Veri yok | |
| Independent Director | 3.2yrs | US$69.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.8yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 1.8yrs | Veri yok | Veri yok |
4.8yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: CTMX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.8 yıldır).